Advertisement


Jonathan Chen, MD, PhD, on NSCLC: Predicting Response to Immunotherapy

SITC 2022

Advertisement

Jonathan Chen, MD, PhD, of Massachusetts General Hospital, discusses “immunity hubs” that interact with a reservoir of stem-like CD8 T cells and appear to be associated with subsequent response to anti–PD-1 blockade in patients with non–small cell lung cancer. Hybrid hubs, Dr. Chen says, are a favorable class of immunity hub notable for CD8-positive and TCF7-positive cells, as well as CCL19 expression (Abstract 956).



Related Videos

Immunotherapy
Lung Cancer

Talal El Zarif, MD, and Abdul Rafeh Naqash, MD: For Patients Living With HIV and Cancer, New Data on Immune Checkpoint Inhibitors

Talal El Zarif, MD, of Dana-Farber Cancer Institute, and Abdul Rafeh Naqash, MD, of Stephenson Cancer Center at The University of Oklahoma, discuss the results of their cohort study of patients living with HIV and metastatic non–small cell lung cancer, who are often underrepresented in clinical trials, and the safety and efficacy of treating this unique population with immune checkpoint inhibitors (ICIs). The data showed that patients living with HIV and lung cancer had similar toxicity profiles and clinical outcomes as did those who did not have HIV and received ICIs (Abstract 437).

Immunotherapy

Michael A. Postow, MD, on Using the Novel Radiotracer Crefmirlimab Berdoxam for Imaging to Assess Immunotherapy Responsiveness

Michael A. Postow, MD, of Memorial Sloan Kettering Cancer Center, discusses new findings on the correlation between CD8 cell PET imaging with zirconium-89–crefmirlimab berdoxam and CD8 cell immunohistochemistry in patients with advanced cancer receiving immunotherapy. Noninvasive CD8 PET scanning with crefmirlimab berdoxam permits whole-patient, longitudinal CD8 assessment, which is currently under investigation as a biomarker for immunotherapy responsiveness and may be a useful tool for immunotherapy development and clinical management (Abstract 1472).

Skin Cancer
Immunotherapy

Saman Maleki, PhD, on Melanoma: Reducing Primary Resistance to Immunotherapy

Saman Maleki, PhD, of Canada’s Western University and Lawson Health Research Institute, discusses modifying the gut microbiome in patients with advanced melanoma to induce a response to anti–PD-1 therapy and potentially reduce primary resistance to immunotherapy. A fecal microbiota transplant from healthy donors before treatment appears to be beneficial (Abstract 614).

Lung Cancer
Immunotherapy

Wade T. Iams, MD, on NSCLC: Combining an Antigen-Presenting Cell Activator With Pembrolizumab

Wade T. Iams, MD, of Vanderbilt University Medical Center, discusses phase II efficacy results from the first-line non–small cell lung cancer cohort of the TACTI-002 study. The results suggest that when combined with pembrolizumab, eftilagimod alpha yielded encouraging efficacy across all PD-L1 levels, including patients with PD-L1 low and PD-L1 negative disease (Abstract 1470).

Breast Cancer
Immunotherapy

Julia Tchou, MD, PhD, on Triple-Negative Breast Cancer: Radiation Boost Plus Pembrolizumab

Julia Tchou, MD, PhD, of the University of Pennsylvania, discusses preliminary results of the phase Ib/II BreastVax study, which suggested a single preoperative pembrolizumab dose plus a tumor-targeting radiation boost may result in pathologic response in patients with early-stage triple-negative breast cancer (Abstract 644).

Advertisement

Advertisement



Advertisement